Janssen Pharmaceutical K.k.
Clinical trials sponsored by Janssen Pharmaceutical K.k., explained in plain language.
-
New drug delivery system targets bladder cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment called TAR-210 in 5 Japanese patients with bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to check safety and toler…
Phase: PHASE1 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New hope for rare, severe psoriasis: phase 3 trial underway
Disease control OngoingThis study tests an experimental drug, JNJ-77242113, in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The goal is to see if the drug can improve skin symptoms by week 16. Participants must have a diag…
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Experimental gene therapy targets rare blindness in japanese patients
Disease control OngoingThis study tests a gene therapy for a rare inherited eye disease called X-linked retinitis pigmentosa, which causes gradual vision loss. The treatment delivers a working gene to the retina using a harmless virus. The study involves 4 Japanese participants aged 5 or older and focu…
Phase: PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC